Attorney General William Tong of Connecticut has begun his term as President of the National Association of Attorneys General (NAAG) after being unanimously elected by attorneys general from both major parties.
Tong will lead a bipartisan leadership team. The group includes South Dakota Attorney General Marty Jackley, who is President-elect; District of Columbia Attorney General Brian Schwalb, serving as Vice President; and New Hampshire Attorney General John Formella, who is past-President.
As part of his new role, Tong announced that his 2026 Presidential Initiative will focus on “Driving Down Costs for American Families.” This initiative aims to highlight legal actions taken by attorneys general across the country to address financial pressures faced by households. Issues such as generic drug price-fixing, housing costs influenced by algorithms, organized retail crime affecting everyday goods prices, unaffordable energy costs, healthcare consolidation, and price gouging will be examined. The initiative plans to showcase bipartisan efforts and culminate in a national forum scheduled for summer 2026 in Connecticut.
“Now more than ever, I am honored by this unanimous and bipartisan support from attorneys general across the country. From Big Tech to Big Pharma, this role reflects and ensures Connecticut’s role at the front and center of all of the major multistate legal actions and efforts. For years, American families have been squeezed by high costs from all directions. This year, my Presidential Initiative will address how attorneys general can harness our law enforcement authority to drive down those costs. As we take on some of the biggest corporations and powerful forces, I am honored by this opportunity to lead both Democrats and Republicans in delivering for American families,” said Attorney General Tong.
Tong’s election as NAAG president highlights his involvement in significant national cases and investigations. These include holding companies accountable for their roles in the opioid crisis, promoting competition within the generic drug industry, challenging dominant technology firms on antitrust grounds, pushing for better data protection practices among corporations, addressing health and environmental concerns related to chemical pollution, and seeking accountability from social media companies regarding youth safety.